Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease

Dénes Zádori, Andrea Geisz, E. Vámos, L. Vécsei, P. Klivényi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Huntington's disease (HD) is one of the chronic devastating neurodegenerative disorders. The pathophysiological processes clearly involve both excitotoxicity and reduced gene transcription due to the decreased level of histone acetylation, accompanied by the loss of γ-aminobutyric acidergic (GABAergic) medium-sized spiny neurons in the striatum as a pathological hallmark of HD. Thus, the antiepileptic drug valproate, which has proved GABAergic, antiexcitotoxic and histone deacetylase inhibitor effects, might be of value by exerting a beneficial neuroprotective effect. We have now tested this drug in the N171-82Q transgenic mouse model of HD, following its chronic intraperitoneal administration in a daily dose of 100 mg/kg. Valproate significantly prolonged the survival of the transgenic mice and significantly ameliorated their diminished spontaneous locomotor activity, without exerting any noteworthy side-effect on their behaviour or the striatal dopamine content at the dose administered. The beneficial effect of valproate is probably explained by its complex pharmacological activity. As several previous clinical trials carried out with valproate did not indicate any positive effect in HD, it is worth considering the design of new studies based on a well-planned treatment regime with higher dose, using valproate in monotherapy or in combination therapy with a high number of participating patients.

Original languageEnglish
Pages (from-to)148-153
Number of pages6
JournalPharmacology, Biochemistry and Behavior
Volume94
Issue number1
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Huntington Disease
Valproic Acid
Transgenic Mice
Survival
Corpus Striatum
Acetylation
Histone Deacetylase Inhibitors
Neuroprotective Agents
Transcription
Locomotion
Neurodegenerative Diseases
Anticonvulsants
Histones
Neurons
Dopamine
Genes
Clinical Trials
Pharmacology
Therapeutics
Pharmaceutical Preparations

Keywords

  • Huntington's disease
  • N171-82Q
  • Transgenic mice
  • Valproate

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. / Zádori, Dénes; Geisz, Andrea; Vámos, E.; Vécsei, L.; Klivényi, P.

In: Pharmacology, Biochemistry and Behavior, Vol. 94, No. 1, 11.2009, p. 148-153.

Research output: Contribution to journalArticle

@article{5ba5984f5c6b4fda9d2c2ac8f7560e40,
title = "Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease",
abstract = "Huntington's disease (HD) is one of the chronic devastating neurodegenerative disorders. The pathophysiological processes clearly involve both excitotoxicity and reduced gene transcription due to the decreased level of histone acetylation, accompanied by the loss of γ-aminobutyric acidergic (GABAergic) medium-sized spiny neurons in the striatum as a pathological hallmark of HD. Thus, the antiepileptic drug valproate, which has proved GABAergic, antiexcitotoxic and histone deacetylase inhibitor effects, might be of value by exerting a beneficial neuroprotective effect. We have now tested this drug in the N171-82Q transgenic mouse model of HD, following its chronic intraperitoneal administration in a daily dose of 100 mg/kg. Valproate significantly prolonged the survival of the transgenic mice and significantly ameliorated their diminished spontaneous locomotor activity, without exerting any noteworthy side-effect on their behaviour or the striatal dopamine content at the dose administered. The beneficial effect of valproate is probably explained by its complex pharmacological activity. As several previous clinical trials carried out with valproate did not indicate any positive effect in HD, it is worth considering the design of new studies based on a well-planned treatment regime with higher dose, using valproate in monotherapy or in combination therapy with a high number of participating patients.",
keywords = "Huntington's disease, N171-82Q, Transgenic mice, Valproate",
author = "D{\'e}nes Z{\'a}dori and Andrea Geisz and E. V{\'a}mos and L. V{\'e}csei and P. Kliv{\'e}nyi",
year = "2009",
month = "11",
doi = "10.1016/j.pbb.2009.08.001",
language = "English",
volume = "94",
pages = "148--153",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease

AU - Zádori, Dénes

AU - Geisz, Andrea

AU - Vámos, E.

AU - Vécsei, L.

AU - Klivényi, P.

PY - 2009/11

Y1 - 2009/11

N2 - Huntington's disease (HD) is one of the chronic devastating neurodegenerative disorders. The pathophysiological processes clearly involve both excitotoxicity and reduced gene transcription due to the decreased level of histone acetylation, accompanied by the loss of γ-aminobutyric acidergic (GABAergic) medium-sized spiny neurons in the striatum as a pathological hallmark of HD. Thus, the antiepileptic drug valproate, which has proved GABAergic, antiexcitotoxic and histone deacetylase inhibitor effects, might be of value by exerting a beneficial neuroprotective effect. We have now tested this drug in the N171-82Q transgenic mouse model of HD, following its chronic intraperitoneal administration in a daily dose of 100 mg/kg. Valproate significantly prolonged the survival of the transgenic mice and significantly ameliorated their diminished spontaneous locomotor activity, without exerting any noteworthy side-effect on their behaviour or the striatal dopamine content at the dose administered. The beneficial effect of valproate is probably explained by its complex pharmacological activity. As several previous clinical trials carried out with valproate did not indicate any positive effect in HD, it is worth considering the design of new studies based on a well-planned treatment regime with higher dose, using valproate in monotherapy or in combination therapy with a high number of participating patients.

AB - Huntington's disease (HD) is one of the chronic devastating neurodegenerative disorders. The pathophysiological processes clearly involve both excitotoxicity and reduced gene transcription due to the decreased level of histone acetylation, accompanied by the loss of γ-aminobutyric acidergic (GABAergic) medium-sized spiny neurons in the striatum as a pathological hallmark of HD. Thus, the antiepileptic drug valproate, which has proved GABAergic, antiexcitotoxic and histone deacetylase inhibitor effects, might be of value by exerting a beneficial neuroprotective effect. We have now tested this drug in the N171-82Q transgenic mouse model of HD, following its chronic intraperitoneal administration in a daily dose of 100 mg/kg. Valproate significantly prolonged the survival of the transgenic mice and significantly ameliorated their diminished spontaneous locomotor activity, without exerting any noteworthy side-effect on their behaviour or the striatal dopamine content at the dose administered. The beneficial effect of valproate is probably explained by its complex pharmacological activity. As several previous clinical trials carried out with valproate did not indicate any positive effect in HD, it is worth considering the design of new studies based on a well-planned treatment regime with higher dose, using valproate in monotherapy or in combination therapy with a high number of participating patients.

KW - Huntington's disease

KW - N171-82Q

KW - Transgenic mice

KW - Valproate

UR - http://www.scopus.com/inward/record.url?scp=70349195820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349195820&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2009.08.001

DO - 10.1016/j.pbb.2009.08.001

M3 - Article

C2 - 19698736

AN - SCOPUS:70349195820

VL - 94

SP - 148

EP - 153

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 1

ER -